Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:301093'
s Net Margin % Range Over the Past 10 Years
Min: 7.03 Med: 18.93 Max: 26.32
Current: 7.03
SZSE:301093's Net Margin % is ranked better than 62.45% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 2.24
vs SZSE:301093: 7.03
Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Jiangsu Hualan New Pharmaceutical Material Co Net Margin % Related Terms
Jiangsu Hualan New Pharmaceutical Material Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hualan New Pharmaceutical Material Co Net Margin % Chart
Jiangsu Hualan New Pharmaceutical Material Co Annual Data
SZSE:301093 vs ISRG, BDX, MDLN: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Jiangsu Hualan New Pharmaceutical Material Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hualan New Pharmaceutical Material Co Net Margin % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093) has a Net Margin % of 0.47% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Jiangsu Hualan New Pharmaceutical Material Co and its competitors. This is 98% below median its historical median of 18.93. Over the past decade, Jiangsu Hualan New Pharmaceutical Material Co's Net Margin % has ranged from 7.03 to 26.32. According to the industry distribution chart, Jiangsu Hualan New Pharmaceutical Material Co ranks #306 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 37.5%.
Is Jiangsu Hualan New Pharmaceutical Material Co's Net Margin % too high?
Jiangsu Hualan New Pharmaceutical Material Co's current Net Margin % of 0.47% is 98% below median its 10-year median of 18.93. Over the past 10 years, this metric has ranged from a low of 7.03 to a high of 26.32. The Medical Devices & Instruments industry median Net Margin % is 2.24. Jiangsu Hualan New Pharmaceutical Material Co's value of 0.47% is 79% below this industry median. Based on the distribution chart, Jiangsu Hualan New Pharmaceutical Material Co ranks #306 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Jiangsu Hualan New Pharmaceutical Material Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hualan New Pharmaceutical Material Co's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Jiangsu Hualan New Pharmaceutical Material Co ranks #306 out of 815 companies for Net Margin %. This puts Jiangsu Hualan New Pharmaceutical Material Co in the upper half of its industry. The industry median Net Margin % is 2.24. Jiangsu Hualan New Pharmaceutical Material Co's value of 0.47% is 79% below this benchmark. Historically, Jiangsu Hualan New Pharmaceutical Material Co's own Net Margin % has ranged from 7.03 to 26.32 over the past decade. While the company's 10-year median is 18.93 vs. the industry median of 2.24, Jiangsu Hualan New Pharmaceutical Material Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.24, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hualan New Pharmaceutical Material Co's current Net Margin % of 0.47% is 79% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Jiangsu Hualan New Pharmaceutical Material Co and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hualan New Pharmaceutical Material Co's current Net Margin % is 0.47%, which is 98% below median its own 10-year median of 18.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hualan New Pharmaceutical Material Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥23.79, compared to a current price of ¥74.73 — trading 214.1% above its estimated fair value. The current Net Margin % is 0.47%, which is 98% below median its 10-year median of 18.93 and 79% below the Medical Devices & Instruments industry median of 2.24. Jiangsu Hualan New Pharmaceutical Material Co's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093), the current Net Margin % is 0.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hualan New Pharmaceutical Material Co stock appears to be overvalued.
The current stock price of ¥74.73 is trading 214.1% above its estimated GF Value™ of ¥23.79.
GuruFocus considers Jiangsu Hualan New Pharmaceutical Material Co to be Significantly Overvalued.
Key valuation signals for SZSE:301093:
Net Margin %: 0.47% (98% below median its 10-year median of 18.93)
GF Value™: ¥23.79 vs. price of ¥74.73 (214.1% above fair value)
Industry Position: 79% below the Medical Devices & Instruments median (#306 of 815)
No single metric tells the full story. See the SZSE:301093 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hualan New Pharmaceutical Material Co Ltd is engaged in direct contact with the research and development, production and sales of packaging materials for injection drugs. The company's main products are medicinal sealing elastomers such as film-coated rubber plugs for high and middle end injections, conventional rubber plugs, pre-filled pistons, and silicone seals.
69GF Score
Get the complete analysis for SZSE:301093
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301093 has been successfully added to your 
